Mereo Biopharma Group PLC
NASDAQ:MREO
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
UK |
Mereo Biopharma Group PLC
NASDAQ:MREO
|
434.8m USD | -9.9 | ||
US |
Abbvie Inc
NYSE:ABBV
|
283.3B USD | 17.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
164.8B USD | 17 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.9B USD | 33.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.3B USD | 26.8 | ||
AU |
CSL Ltd
ASX:CSL
|
135.1B AUD | 181.5 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.9B USD | 11.9 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
46.7B USD | -11.9 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -61.5 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32B USD | 29.9 | ||
KR |
Celltrion Inc
KRX:068270
|
40.3T KRW | 670.4 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.